<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - Paediatric medicines (debate) - Wednesday, 14 December 2016</title><meta name="title" content="Verbatim report of proceedings - Paediatric medicines (debate) - Wednesday, 14 December 2016" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2016 - Source: European Parliament" /><meta name="available" content="14-12-2016" /><meta name="sipade-leg" content="8" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - Paediatric medicines (debate) - Wednesday, 14 December 2016" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-8-2016-12-14-ITM-024_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li><a title="hr - hrvatski" class="hr on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_HR.html">hr - hrvatski</a></li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-8-2016-12-14-ITM-024_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2016-12-14-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2016-12-14-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2016-12-14-ITM-023_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2016-12-14-ITM-023_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-8-2016-12-14-ITM-025_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-8-2016-12-14-ITM-025_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2016-12-14_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2016-12-14_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table>
                <table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="left"><span class="contents">Procedure : </span><a class="ring_ref_link" href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2016/2902(RSP)">2016/2902(RSP)</a></td><td align="right"><table align="right" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><img src="/doceo/data/img/ring_tabs_left_doc_unselected.gif" height="19" width="4" alt="" /></td><td class="Tabs_doc_unselected"><img src="/doceo/data/img/ring_navi.gif" width="17" height="14" alt="" />Document stages in plenary</td><td valign="middle"><img src="/doceo/data/img/ring_tabs_right_doc_unselected.gif" height="19" width="4" alt="" /></td></tr></tbody></table></td></tr></tbody></table><table class="doc_box_header" border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="ring_multiple_bg" colspan="7" valign="top">Select a document :
            <select class="ring_list" onChange="window.location.replace(this.value);"><option selected="selected">Select...</option><option value="/doceo/document/O-8-2016-000135_EN.html" selected="selected">O-000135/2016</option><option value="/doceo/document/B-8-2016-1340_EN.html">B8-1340/2016</option></select></td></tr><tr><td width="25%" valign="top" class="ring_step_bg1" nowrap="nowrap"><p class="ring_step_title">Texts tabled :</p>
                        <a href="/doceo/document/O-8-2016-000135_EN.html" class="ring_ref_link">O-000135/2016</a><span class="ring_ref_nolink"> (B8-1818/2016)</span><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg1.gif)"><img src="/doceo/data/img/ring_flech1.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg2" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Debates :</p>
                        <a href="/doceo/document/PV-8-2016-12-14-ITM-024_EN.html" class="ring_ref_link">PV 14/12/2016 - 24</a><br />
                        <a class="ring_ref_selected">CRE 14/12/2016 - 24</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg2.gif)"><img src="/doceo/data/img/ring_flech2.gif" width="13" height="22" border="0" alt="" /></td><td class="ring_step_bg3" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Votes :</p></td><td width="19" style="background-image:url(/doceo/data/img/ring_bg3.gif)"><img src="/doceo/data/img/ring_flech3.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg4" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Texts adopted :</p></td></tr></tbody></table><br />
                
            <table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Wednesday, 14 December 2016 - Strasbourg</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 24. Paediatric medicines (debate)</td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table cellSpacing="0" cellPadding="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:15:43&amp;playerEndTime=20161214-22:44:12" target="_blank"><img width="29" height="20" src="/doceo/data/img/vod_all_speakers_left.gif" border="0" /></a></td><td class="switch_button_pv_cre"><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:15:43&amp;playerEndTime=20161214-22:44:12" target="_blank">Video of the speeches</a></td><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:15:43&amp;playerEndTime=20161214-22:44:12" target="_blank"><img width="5" height="20" src="/doceo/data/img/switch_pv_cre_right.gif" border="0" /></a></td></tr></table></td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table align="right" cellpadding="0" cellspacing="0"><tr><td><a href="/doceo/document/PV-8-2016-12-14-ITM-024_EN.html" title="Minutes"><img src="/doceo/data/img/switch_pv_cre_left.gif" width="22" height="20" border="0" alt="" /></a></td><td class="switch_button_pv_cre"><a href="/doceo/document/PV-8-2016-12-14-ITM-024_EN.html" title="Minutes">PV</a></td><td><a href="/doceo/document/PV-8-2016-12-14-ITM-024_EN.html" title="Minutes"><img src="/doceo/data/img/switch_pv_cre_right.gif" width="5" height="20" border="0" alt="" /></a></td></tr></table></td></tr></table>
<a name="3-1045-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96864.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:15:43&amp;playerEndTime=20161214-22:15:56" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Presidente. –</span></span>   L'ordine del giorno la discussione sull'interrogazione con richiesta di risposta orale alla Commissione sui medicinali per uso pediatrico di Giovanni La Via, Françoise Grossetête, Elena Gentile, Bolesław G. Piecha, Frédérique Ries, Stefan Eck, Joëlle Mélin, a nome della commissione per l'ambiente, la sanità pubblica e la sicurezza alimentare (<a href="/doceo/document/O-8-2016-000135_EN.html">O-000135/2016</a> - B8-1818/2016).</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1046-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96816.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:15:56&amp;playerEndTime=20161214-22:18:23" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Giovanni La Via, </span></span>  <span class="italic">autore</span><span class="bold">.</span> – Signor Presidente, onorevoli colleghi, Commissario, con questa interrogazione orale poniamo una serie di richieste alla Commissione europea per migliorare la normativa sui medicinali pediatrici, chiaramente per noi rappresentanti del popolo europeo, ma anche per i cittadini, molto importante.</p>
<p class="contents">Si tratta di un dovere che dobbiamo assumere in quanto politici, legislatori, ma anche genitori per tutti i piccoli ammalati al fine di salvare, per quanto possibile, tante giovani vite. Il regolamento ha avuto un impatto significativo sullo sviluppo dei medicinali per uso pediatrico, fungendo da motore per molte aziende farmaceutiche in materia di sviluppo di prodotto e di progetti di ricerca, il cui numero è notevolmente aumentato.</p>
<p class="contents">Ci sono però dei miglioramenti e delle modifiche che sono possibili e che noi parlamentari europei chiediamo con forza. Chiediamo alla Commissione di presentare una relazione dettagliata che individui in modo completo e analizzi nel dettaglio gli ostacoli che oggi si frappongono all'innovazione nel settore dei medicinali per uso pediatrico. </p>
<p class="contents">Chiediamo inoltre di esaminare, sulla base di tali risultati, la possibilità di apportare modifiche, anche attraverso una revisione legislativa, del regolamento sui medicinali pediatrici, che tenga nella dovuta considerazione una serie di fatti importanti, come i piani di sviluppo pediatrico basati sul meccanismo d'azione e non solo sul tipo di malattia, piani d'indagine pediatrica più tempestivi e realizzabili, incentivi alla ricerca e strategie per evitare l'uso <span class="italic">off label</span> quando esistono medicinali pediatrici autorizzati. Questo porterà a una serie di benefici in termini di vite salvate in oncologia pediatrica, ad esempio, come Lei sa bene.</p>
<p class="contents">Chiediamo anche che la Commissione consideri di modificare il regolamento affinché sperimentazioni promettenti non vengano interrotte prematuramente a causa di risultati insoddisfacenti sugli adulti e per sostenere la ricerca clinica pediatrica di elevata qualità. Dobbiamo accelerare lo sviluppo di farmaci pediatrici, in particolare quei farmaci per la neonatologia e i tumori infantili. </p>
<p class="contents">Ringrazio sin da adesso la Commissione per le risposte che vorrà darci e siamo certi che si adopererà per andare a fondo su questo tema, che è una reale necessità per tutti i cittadini europei.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1047-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:18:25&amp;playerEndTime=20161214-22:21:36" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Vytenis Povilas Andriukaitis,</span></span>   <span class="italic">Member of the Commission</span><span class="bold">.</span> – Mr President, ensuring the health of children and maximising their life potential is our common goal. The Commission welcomes this debate. It confirms the shared interest of both our institutions to secure the best outcome for children. This debate comes at a timely moment; indeed the Commission is preparing a second report to the Council and Parliament on the Paediatric Medicines Regulation. </p>
<p class="contents">As honourable Members will know, the Regulation aims to ensure that we can provide children with quality medicines. This legislative stimulus was deemed necessary because pharmaceutical companies tend to focus mainly on adults. The Regulation succeeded in putting the spotlight on developing paediatric therapies. It was a game—changer; companies can no longer ignore paediatric development. It put an end to the dogma that children should be protected from clinical research. Instead, children merit the same evidence—based therapies as other age groups. It increased paediatric discharge also in the most vulnerable population of neonates.</p>
<p class="contents">We now see an increasing number of new products for children entering the market. Indeed, more than 900 paediatric development programmes have been agreed under the Regulation, and more than 100 have been completed in recent years. </p>
<p class="contents">But there are also, of course, limitations to what the Regulation can achieve. As there is an obligation for it not to regard the development of adult medicines, the additional paediatric research may not address pressing paediatric needs, especially in diseases that occur only in children, such as many paediatric cancers.</p>
<p class="contents">We are looking closely as this issue in the context of drawing up the second report. At the same time, we are analysing economic impacts with a particular focus on the rewards and incentives. Last month, the Commission launched a public consultation which will run until February 2017. This exercise is important as it gives everybody an opportunity for their voice to be heard before finalisation of the report. The Commission cannot therefore draw conclusions at this stage. We first needed to compare for you the data and gather experiences. </p>
<p class="contents">The Commission is committed to presenting, in the course of 2017, a detailed report on the Paediatric Regulation. It is our obligation, and on the basis of its findings we will be better placed to continue informed discussions on the best way forward. We are working on common discussions on those issues. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1048-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/2025.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:21:44&amp;playerEndTime=20161214-22:24:06" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Françoise Grossetête, </span></span>  <span class="italic">au nom du groupe PPE</span><span class="bold">.</span> – Monsieur le Président, Monsieur le Commissaire, le 7 juin 2010, à l’âge de 14 ans, Margaux est décédée d’une tumeur agressive au cerveau, malheureusement incurable. Sa mère a voulu continuer à se battre, à travers l’association «Imagine for Margaux». C’est son combat, dont je veux aujourd’hui me faire l’écho.</p>
<p class="contents">Comme elle, des milliers de parents en Europe perdent chaque année leurs enfants atteints de maladies graves, faute de traitements efficaces.</p>
<p class="contents">Comment peut-on continuer à accepter que des enfants meurent de maladies que l’on sait soigner chez les adultes ? Malgré les progrès qu’a permis le règlement pédiatrique de 2006, en obligeant par exemple les industriels à conduire des plans d’investigation pédiatrique, la recherche en pédiatrie reste trop rare.</p>
<p class="contents">Alors que la Commission doit bientôt procéder – vous l’avez dit, Monsieur le Commissaire – à l’évaluation du règlement en vigueur, il est indispensable d’y apporter des améliorations substantielles. </p>
<p class="contents">La recherche n’est encore pas suffisamment encouragée et trop d’exemptions sont accordées qui permettent aux laboratoires de ne pas conduire les plans d’investigation pédiatrique ou de ne pas les mener à terme.</p>
<p class="contents">La première urgence est d’utiliser les flexibilités de la législation actuelle pour baser l’obligation de conduire des plans d’investigation pédiatrique sur le mécanisme d’action de la molécule et pour rendre ces derniers plus réalistes et plus faisables.</p>
<p class="contents">La seconde urgence est de construire un système véritablement incitatif qui, d’une part, sanctionne ceux qui ne jouent pas le jeu et, d’autre part, encourage les laboratoires à développer des indications uniquement pédiatriques et pas forcément calquées sur les produits pour adultes. Une véritable réflexion doit être menée à ce propos. </p>
<p class="contents">«Vas-y, bats-toi et gagne»: ces mots, que l’on a retrouvés dans les carnets de Margaux, nous en sommes aujourd’hui les dépositaires. Il nous revient de nous battre et de gagner pour les enfants malades. Monsieur le Commissaire, je compte vraiment sur vous, vous devez absolument nous aider à ne pas perdre de temps dans ce domaine. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1049-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124847.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:24:11&amp;playerEndTime=20161214-22:26:08" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Elena Gentile, </span></span>  <span class="italic">a nome del gruppo S&amp;D</span><span class="bold">.</span> – Signor Presidente, onorevoli colleghi, i dati sono drammaticamente veri.</p>
<p class="contents">Ogni anno in Europa seimila pazienti in età pediatrica e adolescenziale perdono la vita. Molti fortunatamente sopravvivono, restituiti ad una vita normale, ma un numero considerevole vedrà la loro vita segnata da complicazioni che incidono pesantemente sulla qualità della vita. Il network europeo per l'oncoematologia pediatrica ha posto l'esigenza di promuovere un piano strategico sostenibile di lungo termine per rendere più efficaci le cure e quindi migliorare la prognosi per quei pazienti nei confronti dei quali i trattamenti attualmente a disposizione non riescono a centrare l'obiettivo di restituire loro un percorso di vita libero da complicazioni.</p>
<p class="contents">Poche e insufficienti le risorse a disposizione per la ricerca e la sperimentazione. Vi è dunque la necessità di favorire una nuova consapevolezza delle istituzioni europee per far sì che l'oncoematologia pediatrica non venga considerata residuale nell'agenda politica europea, ma occupi un ruolo prioritario. A chiederlo non sono solo i ricercatori e i critici del settore, ma le numerosissime associazioni dei genitori presenti negli Stati membri che sostengono i punti chiave di questa nuova strategia finalizzata, appunto, a promuovere trattamenti innovativi e una ricerca orientata a una più puntuale conoscenza della biologia delle neoplasie collegata al meccanismo di azione del farmaco.</p>
<p class="contents">Sostenere la rete europea della ricerca pubblica in connessione con gli istituti di diagnosi e cura, stabilendo una relazione con il sistema dell'industria del farmaco, semplificando le procedure, velocizzando i passaggi amministrativi: mi pare, ci pare questo un obiettivo più che sostenibile.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1050-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124863.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:26:12&amp;playerEndTime=20161214-22:27:44" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Stefan Eck, </span></span>  <span class="italic">im Namen der GUE/NGL-Fraktion</span><span class="bold">.</span> – Herr Präsident, Herr Kommissar, verehrte Kolleginnen und Kollegen! Kinder benötigen besondere Fürsorge, weil sie unsere Zukunft sind. Die bittere Realität: Nur eines von zehn Kindern in der EU, die an Krebs erkranken, wird geheilt. Die Entwicklung innovativer Therapien und spezieller Medikamente für krebskranke Kinder muss im Fokus der Pharmakonzerne stehen. Das schulden wir diesen Kindern und ihren Eltern. Deshalb freue ich mich besonders, dass dieser Bericht auch geeignet ist, die pädiatrische Onkologie voranzutreiben.</p>
<p class="contents">Es ist aber wichtig, an folgenden Grundsätzen festzuhalten: öffentlich zugängliche Evaluierung der Entwicklungskosten, volle Transparenz der klinischen Kosten und ein Assessment darüber, wie Subventionen und öffentliche Mittel effizient eingesetzt werden können.</p>
<p class="contents">Abschließend möchte ich Ihnen allen schöne Feiertage und ein gutes neues Jahr wünschen, aber vor allem Gesundheit. Deshalb habe ich mir erlaubt, liebe Kolleginnen und Kollegen, Ihnen ein veganes Kochbuch in Ihr Postfach zu legen, weil die Ernährung großen Einfluss auf die Gesundheit hat – auf die Gesundheit von Erwachsenen und auf die Gesundheit von Kindern.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1051-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124844.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:27:39&amp;playerEndTime=20161214-22:29:53" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Piernicola Pedicini, </span></span>  <span class="italic">a nome del gruppo EFDD</span><span class="bold">.</span> – Signor Presidente, onorevoli colleghi, dieci anni fa la Commissione ha adottato il regolamento relativo ai medicinali per uso pediatrico.</p>
<p class="contents">Noi non neghiamo che questo regolamento abbia contribuito a migliorare la situazione generale e a rafforzare la cooperazione in materia di sviluppo di questi medicinali ma, dopo dieci anni, è necessario un riesame critico di questo testo per eliminare le lacune finora riscontrate.</p>
<p class="contents">I bambini, infatti, sono il gruppo più vulnerabile della popolazione e ci sono differenze sostanziali rispetto agli adulti sul piano sia fisiologico sia psicologico. Per questo noi chiediamo la massima attenzione su questo tema che non ammette temporeggiamenti da parte delle istituzioni. Parliamo del numero esiguo di piani d'indagine pediatrica completati fino ad ora e del differimento sistematico delle indagini pediatriche, per esempio.</p>
<p class="contents">Nel campo della ricerca, poi, il problema è sempre lo stesso. Se lo sviluppo di nuove molecole rimane legato all'aspettativa che un prodotto generi un certo profitto noi non andremo mai da nessuna parte. Come già accade per la resistenza agli antibiotici, così succederà e già succede per i farmaci pediatrici. Voglio anche sottolineare che in oncologia pediatrica la conoscenza scientifica dei processi cellulari usati per testare i farmaci per adulti ha una potenziale rilevanza anche per il trattamento dei tumori pediatrici, ma questi farmaci devono essere oggetto di studi clinici specifici per l'uso pediatrico.</p>
<p class="contents">Inoltre molti dei tumori che colpiscono i giovani sono tumori rari e questo è un altro dei fattori per cui le industrie farmaceutiche hanno scarso interesse a sviluppare i medicinali in questo settore. Segnaliamo che anche l'attuale sistema di premi e incentivi può essere usato impropriamente o addirittura abusato da parte delle case farmaceutiche. Noi non diciamo che le compagnie farmaceutiche non debbano guadagnare, ma non possiamo continuare a lasciare la salute pubblica nelle mani delle logiche di mercato. Ed è per questo che rinnoviamo l'invito a considerare l'istituzione di una casa farmaceutica pubblica ed europea.</p>
<p class="contents">Per chiudere, voglio ricordare che alcuni giorni fa la Commissione ha aperto una consultazione pubblica sull'esperienza finora acquisita. Invito tutti, le case farmaceutiche, i medici, gli scienziati, i gruppi di pazienti e i gruppi di genitori con esperienza di difficoltà alle spalle ad inviare i loro contributi alla Commissione entro il 20 febbraio 2017.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1052-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28178.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:29:57&amp;playerEndTime=20161214-22:31:44" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Miroslav Mikolášik (PPE).</span></span>   – Myslím si, že otázka pediatrických liekov a ich výskumu a dostupnosti liekov pre deti na pediatrickú liečbu je stále veľmi akútna. Myslím si, že si musíme uvedomiť, že vlastne treba už prejsť od diskusií k činom. To, že nám Komisia... ešte budeme stále diskutovať a možno vo februári nám niečo predloží. Na môj vkus, je to pomalá reakcia Komisie, prosil by som zrýchliť celý proces. </p>
<p class="contents">Farmaceutický priemysel sa viac venuje výskumu liekov pre dospelých a len veľmi malý podiel je liekov pre deti, ktoré treba liečiť. Vieme, že najčastejšou príčinou po jednom roku života u detí je vlastne rakovina detí a len 10 % takýchto detí je úspešne vyliečených. </p>
<p class="contents">Deti predsa nie sú zmenšení dospelí. Nemôžeme na nich používať lieky pre dospelých len v nejakej menšej dóze. Tu potrebujeme originálny vlastný výskum takýchto nových liečiv, nových molekúl a keď je treba, treba uvoľniť aj molekuly z oblasti generických liekov, aby sme našim deťom pomohli. Je to naša povinnosť urobiť niečo konkrétne a dať aj oveľa viac peňazí do výskumu na nové pediatrické lieky. Prihováram sa, aby sme boli ďaleko praktickejší a ďaleko účinnejší. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1053-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125041.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:31:47&amp;playerEndTime=20161214-22:33:20" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Soledad Cabezón Ruiz (S&amp;D).</span></span>   – Señor Presidente, hoy no tenemos ninguna duda de que el comportamiento de las enfermedades y la respuesta a los tratamientos en los niños son claramente diferentes de los de los adultos, por lo que son necesarios una investigación y un tratamiento específicos. El Real Decreto de 2006 ha producido importantes avances, pero también creo que hay casi consenso en que podemos mejorar y avanzar. Y yo identificaría dos líneas principales.</p>
<p class="contents">Aquí se ha mencionado especialmente una de ellas, que es la necesidad de que las empresas cumplan los planes de investigación pediátricos a fin de dar respuesta a esa diferenciación de las enfermedades entre los adultos y los niños. Pero también hay que hacer mayor hincapié en la investigación de las enfermedades que afectan específicamente a los niños, sobre todo en el campo de la oncología, donde se ha avanzado especialmente. El 80 % de los pacientes pediátricos sobrevive hoy al cáncer, pero, sin embargo, hay aún una falta importante de conocimientos sobre muchas de las enfermedades que les afectan de forma específica.</p>
<p class="contents">Creo, señor Comisario, que tenemos que revisar este marco y dar seguridad en este sentido, tanto en la implementación de los planes de investigación como en la necesidad de poner en marcha incentivos justos, alineados con las prioridades, transparentes y, por supuesto, que den lugar a indemnizaciones justas. También es necesaria una mayor financiación pública, así como impulsar una red europea en la investigación de todo el conjunto de estas enfermedades.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1054-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96897.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:33:25&amp;playerEndTime=20161214-22:34:48" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">John Stuart Agnew (EFDD).</span></span>   – Mr President, I am delivering this speech on behalf of my colleague, Dr Julia Reed. The Paediatric Regulation was adopted 10 years ago to ensure high-quality research into the development of medicines for children and appropriate authorisation of paediatric medicines. However, in 2013 several inadequacies were identified by the Progress Report adopted by the European Commission, especially with regard to paediatric oncology and neonatology. I appreciate that this motion for a resolution investigates this issue and that the development of a policy supporting paediatricians in improving children’s services is of major importance. I also agree with colleagues that children make up the most vulnerable part of the population and that research in the field of paediatric medicine should be given the same parity as adult health research. </p>
<p class="contents">We in UKIP are extremely concerned about the well-being and health of children. However, I firmly believe that this should and would be better done at national level. National parliaments should be the only entities entitled to legislate on this fundamental issue. Every Member State should shape policy and practices in order to provide high quality and sustainable healthcare services for all children in their own country.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1055-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124710.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:34:52&amp;playerEndTime=20161214-22:36:20" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Michaela Šojdrová (PPE).</span></span>   – Vážený pane komisaři, vývoj, výroba a používání léčivých přípravků obecně jsou velmi odbornou sférou a také velmi citlivou, zvláště ve vztahu k dětským pacientům. Smyslem nařízení z roku 2006 je podporovat vývoj léčivých přípravků pro dětskou populaci a získávat nové validní informace o vlastnostech léků určených dětem a získávat informace o používání těchto léků.</p>
<p class="contents">Zpráva z roku 2013 o implementaci tohoto nařízení konstatovala určité nedostatky a zavázala Komisi, aby přijala nová opatření. Ukazuje se, že zatím postup není dostatečně rychlý. Stále chybí informace o vývoji léčivých přípravků a také vývoj těchto nových léčivých přípravků není dostatečně podporován. Myslím, že pan komisař to tady opakovaně slyšel. Jak říká můj kolega, lékař Miroslav Mikulášik, dítě není zmenšený dospělý, proto děti potřebují specifické léčivé přípravky přizpůsobené jejich vývoji a specifickým onemocněním.</p>
<p class="contents">Pane komisaři, děkuji za Vaši odpověď. Ale slyšíte od nás opakovaně, že nejsme spokojeni s rychlostí postupu Komise v této oblasti. Žádáme vás o větší nasazení a podporu výzkumu pediatrických léčivých přípravků.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1056-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125107.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:36:25&amp;playerEndTime=20161214-22:37:51" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Claude Rolin (PPE).</span></span>   – Monsieur le Président, l’ambition du règlement a représenté une réelle avancée, mais, sans vouloir banaliser les progrès qui ont été réalisés, il faut quand même reconnaître que beaucoup, beaucoup trop d’obstacles persistent encore.</p>
<p class="contents">Il est absolument nécessaire de faciliter l’accessibilité des médicaments aux enfants, tout en se dotant de garanties suffisantes au niveau de la vérification de la sécurité. Dans certains États membres, dont le mien notamment, l’obtention du remboursement d’un médicament pour les enfants est conditionnée à l’affirmation, par la notice, que celui-ci a bien été étudié dans les tranches d’âge considérées. Il est donc indispensable d’inciter les firmes à faire des études chez les enfants pour les molécules et les indications pertinentes. J’insiste pour qu’il s’agisse d’études pertinentes, dans la mesure où cela ne doit pas conduire à bloquer l’arrivée de médicaments génériques, qui permettent aussi de soulager les budgets.</p>
<p class="contents">Enfin, les sociétés pharmaceutiques doivent absolument, et de façon systématique, élaborer des plans d’investigation pédiatrique. C’est une condition essentielle pour accélérer le développement des traitements à destination des enfants. Nous ne pouvons pas mépriser cet enjeu fondamental. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1057-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:37:50&amp;playerEndTime=20161214-22:38:01" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="italic">Procedura catch-the-eye</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1058-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125069.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:37:58&amp;playerEndTime=20161214-22:39:10" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Νότης Μαριάς (</span></span>  <span class="bold">ECR</span><span class="bold">).</span> – Κύριε Πρόεδρε, διαπιστώνεται ευρωπαϊκή αδιαφορία για τα παιδιατρικά φάρμακα και τα προγράμματα παιδιατρικής έρευνας, ενώ παρατηρείται και μια σχεδόν συστηματική αναβολή των παιδιατρικών μελετών. Η Ευρωπαϊκή Ένωση οφείλει να εξασφαλίσει ότι τα φάρμακα που χρησιμοποιούνται για τη θεραπευτική αγωγή των παιδιών θα τηρούν τις ύψιστες προδιαγραφές και θα υποβάλλονται σε υψηλής ποιότητας δεοντολογική έρευνα. Επιπλέον η Ένωση πρέπει να εξασφαλίσει ότι όλα τα παιδιά θα έχουν πρόσβαση στην απαραίτητη φαρμακευτική αγωγή και στα εμβόλια που χρειάζονται. Στην Ελλάδα οι ελλείψεις σε παιδιατρικά φάρμακα και εμβόλια είναι σοβαρές. Η κατάσταση μπορεί να λάβει απρόβλεπτες συνέπειες, καθώς οι ελλείψεις παιδικών εμβολίων, όπως της ηπατίτιδας Β, σε περιοχές όπου υπάρχει μεγάλος αριθμός προσφύγων είναι ιδιαίτερα αυξημένες. Ειδικά στη Λέσβο παρατηρείται τεράστια έλλειψη, με τους φαρμακοποιούς να καταθέτουν μηνυτήρια αναφορά κατά της φαρμακευτικής εταιρείας που είναι υπεύθυνη για τη διάθεση φαρμάκων στην Ελλάδα. Το ζήτημα λοιπόν είναι σοβαρό και θα πρέπει να πάρουμε μέτρα για να αποφύγουμε τους κινδύνους για τη δημόσια υγεία των πολιτών και ιδίως των παιδιών.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1059-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124851.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:39:15&amp;playerEndTime=20161214-22:40:36" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nicola Caputo (S&amp;D).</span></span>   – Signor Presidente, onorevoli colleghi, il regolamento sui medicinali pediatrici ha contribuito a migliorare la situazione generale, apportando benefici tangibili per una serie di malattie infantili, ma molti settori non hanno riportato progressi significativi, in particolare l'oncologia pediatrica e la neonatologia.</p>
<p class="contents">Spesso non viene osservato il requisito legale di perseguire lo sviluppo di medicinali per uso pediatrico, in quanto i farmaci sono stati sviluppati in condizioni patologiche tipiche per gli adulti, che non si verificano nei bambini. Si registrano quindi ritardi nell'avvio di studi clinici di farmaci oncologici per l'infanzia perché si attende che il farmaco si mostri promettente nei pazienti oncologici adulti.</p>
<p class="contents">Occorre una revisione legislativa di questo regolamento che tenga nella dovuta considerazione in primo luogo la necessità di basare i piani di sviluppo pediatrico su un meccanismo d'azione, non solo sul tipo di tumore, e in secondo luogo quella di garantire una maggiore tempestività e realizzabilità dei piani d'indagine pediatrica. Particolare attenzione deve essere data infine al sistema di incentivi previsto affinché stimoli maggiormente la ricerca e risponda più efficacemente alle esigenze della popolazione pediatrica, garantendo nel contempo la trasparenza del processo di ricerca e sviluppo.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1060-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:40:34&amp;playerEndTime=20161214-22:40:38" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="italic">(Fine della procedura catch-the-eye)</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1061-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:40:37&amp;playerEndTime=20161214-22:44:12" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Vytenis Povilas Andriukaitis,</span></span>   <span class="italic">Member of the Commission</span><span class="bold">.</span> – Mr President, honourable Members, Mr La Via, I thank you because today we have a good opportunity once again to discuss these very sensitive and very important issues. The health of our children is of vital importance. When they fall sick, we should aim to provide them with high-quality medicines. As you rightly said, Mr Mikolášik, children are without doubt not just small adults; they have their own specific needs. I appreciate Parliament’s initiative to raise this issue during the plenary session tonight. I have taken careful note of your comments and views, and I also think about Margot, whom you mentioned, Ms Grossetête.</p>
<p class="contents">I also appreciate the Parliament’s comments to young people suffering from, for example, narcolepsy. Last Monday I met Members of the European Parliament, Mairead McGuinness and Jørn Dohrmann, together with patient representatives, to discuss this issue. Let me take this opportunity to express once again my sympathy towards all the patients and their families affected by this terrible condition. Remember, colleagues, we are in good time. Last year, in March, we launched European Reference Networks, and more than 300 hospitals voluntarily decided to create such a network. I disagree with those who argue that paediatric oncology is the competence of Member States. Can you imagine the possibility of treating rare diseases and rare paediatric cancers in the smallest countries where they do have enough medical expertise, clinical trials and possibilities to join with researchers? What can they do in Cyprus or in Lithuania, and so on? We need to understand that it is not possible to solve those questions at Member State level alone. No, we will push our resources, our clinical expertise and, of course, possibilities to properly manage the treatment of rare paediatric cancers, rare paediatric diseases and rare genetic diseases. There is no doubt.</p>
<p class="contents">As Mr Mikolášik said, we must be very practical. I agree: we will do it this way. As you know, the Commission takes this issue very seriously and has taken a series of actions to ensure these possibilities and to do our best. Let me repeat: the Commission aims to provide this House and the Council in 2017 with a comprehensive report on the Paediatric Regulation which will serve as a solid basis for future discussions. Thank you once again for your interest. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1062-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96864.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20161214-22:44:01&amp;playerEndTime=20161214-22:44:12" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Presidente. –</span></span>   A conclusione della discussione ho ricevuto una proposta di risoluzione a norma dell’articolo 128, paragrafo 5, del regolamento.</p>
<p class="contents">La votazione si svolgerà giovedì 15 dicembre 2016.</p>
<p class="contents"><span class="bold"><span class="italic">Dichiarazioni scritte (articolo 162)</span></span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-1063-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124970.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Miriam Dalli (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">.</span> – To watch an adult go through the pain and suffering of cancer is heart-breaking. However, to watch a child go through this pain is intolerable. 35 000 Children and young people are every year diagnosed with cancer in Europe. Every year in the European Union we lose 6 000 bright, young souls to this scourge. As Socialists and Democrats we are committed to continue working hard to help improve the quality of life of children with cancer and childhood cancer survivors. </p>
<p class="contents">This is why we firmly believe that it is extremely important for children with cancer to have access to new innovative therapies and drugs that can save their lives. The reality is that today there are limited innovative treatments because of the low profit margins in this area of research. </p>
<p class="contents">We call on the Commission to ensure there are enough funding provisions that support high-quality paediatric clinical research and on the Member States to concretely support research, development and the availability of medicinal products for paediatric use. This is our children’s lives that we are dealing with and we need to ensure that we do our utmost to provide them with the best possible therapies and medicines. </p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td></td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
